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Positron imaging tomography (PET) is the most powerful
functional imaging having very high sensitivity and
specificity depending upon the type of the radiolabelled
probes used. Initially, it was considered as a research
tool; however, over the last two decades it has become
a clinical need. In early 2000, it was further strengthened
by successful union with morphological computerised
tomography (CT), which has resulted in improved
diagnostic accuracy. Reasons for its popularity are the
ability of PET to qualitatively study the perfusion,
metabolism, and various receptors functions with
absolute quantification as well. In PET imaging, we are
detecting two photons of 511 keV moving at 180
degrees in opposite directions, produced as a result
of annihilation of a positron with a free electron.
Simultaneous detection of these photons by nuclear
medicine detectors (scintillator or semiconductor
materials) is the basis of the coincidence imaging (PET
imaging). The number of true coincidence (photons of
same annihilation events) ensures good count statistic,
low noise, and good image resolution.
If we look over the evolution of imaging technology in
medicine, in early 70s we used to have fuzzy and low
resolution CT and PET images. However, over the last
three decades there has been a tremendous
development on technological frontiers resulting in
today's high resolution CT and PET images, individually.
In 2001, medical imaging was further strengthened by
the arrival of first hybrid PET/CT scanner, which has
revolutionised the oncology to a greater extent, and
cardiology and neurology to a lesser extent.
The paraphernalia of a PET/CT facility include: (1)
cyclotron which is used to produce short-lived positron
emitting isotope like Carbon-11 having half-life of 20
minutes and Flourine-18 with half-life of 110 minutes; (2)
radiochemistry unit which is used to label a chemical
substrate or probe with the short-lived positron emitting
isotope produced by the cyclotron; (3) an uptake room in
which patient stays for 55-75 minutes in a calm and
quiet manner after getting PET isotope injection; and
(4) an imaging suite equipped with PET/CT scanner.
Fluorodeoxyglucose (18FDG) is the most commonly
used radiolabelled probe because of the longer half-
life of 18F (110 minutes). Chemically, 18FDG is similar to
glucose except that at carbon-2 level, hydroxyl group is
replaced with 18F. 18FDG competes with normal glucose
and follows the same metabolic pathway except once it
is phosphorylated inside the cell by hexokinase, it is not
further metabolised and stays within the cell which
enables in vivo imaging of 18FDG avid tissue. Primary
purpose of using 18FDG (i.e. radiolabelled glucose) is
that the most of malignant cells use glucose as the
sentinel source of energy with overexpression of
hexokinase and glucose transporters (GLUT). This
process of aerobic glycolysis by tumor cell is called the
Warburg effect.
Patient preparation is very important for PET/CT
imaging as better 18FDG uptake in tumor cell needs
lower serum glucose and insulin levels at the time of its
injection. Fasting for 4 - 6 hours for food is mandatory as
hyperglycemia and hyperinsulinemia would result in
enhanced localisation of 18FDG in non-tumor sites like
skeletal muscles. A fasting blood glucose (FBS) level
less than 200 mg/dl is used as a cut-off by many
laboratories; and procedure is rescheduled, if it is more
than 200 mg. To achieve a FBS < 200 mg/dl is a real
issue in diabetics with inadequate glycemic control.
Good hydration is important as it ensures prompt wash-
out of 18FDG from kidneys because about 50 - 70% of
the injected radioactivity is excreted through the kidneys
within 1 hour after injection. Good hydration minimises
radiation exposure to urinary bladder and improves
image quality as well. The usual injected dose of 18FDG
is about 3 MBq/Kg (European recommendation focused
towards low radiation exposure to patients) or 5 MBq/Kg
(US practice). Once the 18FDG is injected, patient stays
in a calm and quiet manner in an uptake room to allow
better uptake of radiolabelled glucose in glucose
dependent tumor cells. After 55 to 75 minutes of uptake
period, patient is asked to empty the urinary bladder and
then the PET/CT imaging is started. First, a scout CT
image is acquired for image planning, followed by a non-
contrast enhanced CT (NCECT) examination from
midbrain to midthigh in most of oncological cases as per
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recommendation of recent guidelines to minimise the
radiation exposure and contrast associated morbidities,
and also to avoid possible over-estimation of tumor FDG
uptake by computer algorithm. After the NCEC, PET
images are acquired which takes about 10 to 15 minutes
depending upon length of patient and time per bed
position required to cover the body. At the end of
imaging, the computer reconstructs CT and PET images
and during this process CT images are used for
attenuation correction of the PET images, which is a
mandatory step. CT images are also used for anatomical
mapping of PET images which lacks anatomical
information. Advantages of PET images include better
lesion characterisation and detection; and with CT
images, these have high diagnostic accuracy and
clinical information.
In clinical practice, 90% of the PET/CT burden is related
to oncology and 5% each for brain and cardiac imaging.
Recently, 18FDG PET/CT has also been used for
evaluation of pyrexia of unknown origin (PUO). 18FDG-
based PET/CT provides a wide spectrum of indication in
clinical oncology. It may be used for the differentiation
between benign and malignant tumors (although not
very popular) like evaluation of solitary pulmonary
nodule. 18FDG-based PET/CT is an important step in
managing paradigm of various malignancies (more than
17 cancers as per National Comprehensive Cancer
Network guidelines, NCCN). It has an established role in
staging, restaging of non-small-cell lung cancer,
lymphoma, head and neck, esophagus, colorectal and
female genital cancers. Use of PET/CT in the diagnostic
workup results in upstaging in about 20 - 40% cases
(avoid under-treatment) and downstaging in 10% cases
(avoid over-treatment, its cost and morbidity as well).
18FDG-based PET/CT has also an established role in
monitoring therapy response and can stratify the
patients as responder and non-responder in the early
phase of treatment. Therefore, treating oncologist can
always change the therapy regime as per available
information by a PET/CT exam. It also has a very strong
prognostication value as a negative 18FDG PET/CT
study has a significantly high negative predictive value
(NPV) for overall and disease-free survivals. However,
positive predictive value (PPV) is relatively low because
of false-positive results caused by 18FDG uptake by non-
malignant foci, like infection or inflammatory lesions. In
recent days, the 18FDG-based PET/CT has also entered
into the radiation oncology suite due to promising results
of radiation therapy planning using metabolic tumor
volume (MTV) derived from 18FDG PET images. In
theranostics, the positron emitting isotope labelled
peptide and monoclonal antibodies imaging with
PET/CT have been used to select cases of metastatic
neuroendocrine tumors which can be treated using
same probe labelled with particle emitters (Alpha emitter
as Radium-223 or Lutitium-177 as beta emitter).
A normal 18FDG PET/CT shows uniform distribution of
mild intensity of labelled glucose over mediastinum and
liver with variable 18FDG uptake over the myocardium,
depending upon the preparation of the patient. Presence
of tracer in kidneys and urinary bladder is a common
finding; and hydration before and after the injection of the
18FDG is recommended to have quick washout from the
kidneys. Uptake of the 18FDG in the bowel is not
uncommon and more commonly seen in diabetic
patients who have been on metformin for some unknown
reasons. Abnormal focal 18FDG deposit is considered
when it is higher than the background activity
(mediastinal or liver uptake); and reviewing with CT
images of same level provides correct localisation and
diagnostic input based on morphological abnormality (if
present). While interpreting 18FDG PET/CT images, the
reader must be aware of the false-negative findings
which are not unusual, indeed. Some well differentiated
cancers like thyroid, prostate, renal, and NET are not
18FDG avid. Lesions smaller than 8 mm are beyond the
resolution of the current scanners and most importantly
inadequate patient preparation must also be considered
as an important cause of false-negative results. False-
positive findings are seen with areas of physiological
uptake like intraocular muscles, laryngeal activity,
cardiac uptake, or some infective or inflammatory
conditions which are not uncommon in patients with
cancers. It is also not uncommon for the 18FDG to be
taken up by benign tumors like hepatic adenomas or
ovarian follicles.
In addition to the qualitative analyses mentioned above,
semi-quantitative parameters have also been introduced
and considered as one of the major strengths of PET
imaging. The most commonly used semiquantitative
parameter in clinical practice is standardised uptake
value (SUV). SUV is the ratio of the 18FDG, in the region
of interest, divided by the injected 18FDG, divided by
patient's weight. If it is assumed that the distribution of
18FDG is uniform in the body and mass is equivalent to
weight (gm = ml), then SUV is considered equal to 1.
Various types of SUVs are being used like SUVmax,
SUVmean and SUVpeak (depending upon ROI drawn).
SUVmax is the most commonly used parameter
worldwide due to its simplicity albeit lacks reproducibility.
These SUVs are commonly used for response
evaluation in patients receiving chemotherapy or
radiation therapy. Based on differential SUV values
between baseline and follow-up scans, various
response evaluation criteria have been formulated.
However, when comparing the SUV values of 2 PET/CT
of a patient, reader must consider the confounding
factors which could result in different values despite no
significant change in tumor biology. These confounding
factors include calibration of dose calibrator and PET/CT
scanner, fasting blood glucose level, uptake time
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between two studies, partial volume effect for small
lesions, use of oral or intravenous contrast, size of the
ROI, and reconstruction algorithm used for two studies.
To make PET/CT more meaningful, standardisation of
imaging protocols among imaging facilities worldwide is
very important.
18FDG-based PET/CT is the most commonly used
hybrid imaging modality in oncology. It plays an
important role in staging, restaging, response evaluation,
and prognostication of various cancers. Judicious and
rationale use of this tool with high diagnostic accuracy,
ensures optimal selection of therapy and tailoring the
therapy in non-responders in the early phase of
treatment. SUV (SUVmax most commonly used) is a
good semiquantitative metric which is extensively being
used for response evaluation. However, one must not
forget the impact of confounding factors upon these
calculated values. To make PET/CT more meaningful,
standardisation of imaging protocol among imaging
facilities worldwide is very important.
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